Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

icipated benefits of Senomyx's direct sales strategy; the anticipated timing and scope of commercial launch of products containing Senomyx's flavor ingredients, including S6973, S2383, S9632, S6821 and our Savory Flavors; whether the research under the Company's sweet taste research program, including ongoing safety studies and other regulatory-focused activities for S617, will be successful and lead to the commercialization of any new flavor ingredients or natural sweeteners; the progress and capabilities of Senomyx's discovery and development programs generally, including without limitation ongoing research to evaluate and potentially develop new Bitter Blockers and Cooling Agents, as well as our ability to identify proteins primarily involved in the perception of salt taste in humans. Risks that contribute to the uncertain nature of the forward-looking statements include: Senomyx has no experience in manufacturing, marketing, or selling flavor ingredients on a commercial scale and may not successfully implement its direct sales strategy; Senomyx is dependent on its product discovery and development collaborators for all of Senomyx's development revenues; Senomyx is currently dependent on its current and any future product discovery and development collaborators to develop, manufacture, and commercialize any flavor ingredients Senomyx may discover; Senomyx may not be able to establish new collaborations or other business arrangements and/or maintain existing collaborations on acceptable terms;  large companies are typically conservative when implementing changes to their branded products, and may not begin or expand their use of Senomyx flavor ingredients when expected or at all; development activities for newer flavor ingredients, including S617, may not demonstrate an acceptable safety profile or meet other commercialization criteria; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval required for flavor ingredients to
'/>"/>
SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Sales Horizons, a leader in sales ... training programs for companies engaged in complex B2B sales. ... thousands of salespeople over 25 years in market-leading Fortune ... be customized to address the unique sales challenges of ... training program consists of two parts: Mastering the ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... 7, 2011 Reportlinker.com announces that a new ... Industrial Biotechnology China News 1103 ... The Chinese central government was reported to continue ... the Twelfth Five-Year (2011-2015) Plan. This act is ...
... and industrial research scientists and engineers, as well ... encounter a steep learning curve when developing common ... book just published by Springer promises to be ... The new MEMS Materials and Processes Handbook is ...
... The U.S. Food and Drug Administration today approved ... tool to treat brain aneurysms without performing open surgery. ... An aneurysm is a weak, enlarged area in an ... blood pressure can cause it to rupture, which can ...
Cached Biology Technology:Reportlinker Adds Industrial Biotechnology China News 1103 2Reportlinker Adds Industrial Biotechnology China News 1103 3MEMS Materials and Processes Handbook -- a comprehensive, practical resource 2FDA Approves New Device to Treat Brain Aneurysms 2FDA Approves New Device to Treat Brain Aneurysms 3
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... into a multitude of cells types. Researchers would like to ... of mature cells that make up the organs and other ... be long chains of sugars that dangle from proteins on ... of California, San Diego, has created synthetic molecules that can ... easily manipulated to direct the process, they report in the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... , This news release is available ... Medical implants, complex interfaces between brain and machine or ... great potentials, but also give rise to major ethical concerns. ... technischer Systeme mit Lebewesen" (The Chemistry of Cyborgs Interfacing ...
... cells scientists at Brigham and Women,s Hospital and MIT ... following transplantation, potentially making cell therapies, hundreds of which ... more functional and efficient. Associate Professor Jeffrey Karp, ... issue of Nature Protocols how to load ...
... , Jan. 10, 2014   BioNano Genomics announced today ... present at the 32nd Annual J.P. Morgan Healthcare Conference in ... p.m. PST.  About BioNano Genomics ... delivering an altogether better way of gaining a fully informed understanding ...
Cached Biology News:The cyborgs era has started 2The cyborgs era has started 3Harvard scientists control cells following transplantation, from the inside out 2
... Gene Expression (SAGE) is a powerful ... a cost-effective outsourcing solution for sequencing ... Agencourt's SAGE sequencing service provides our ... long Phred20 read lengths (40 SAGE ...
... Sciences can provide custom microplate coating using advanced automated high ... of plate formats. We can also accommodate virtually any lot ... 0.5-320 L):, , 8 ... well microplate, 384 well microplate, ...
... ) The antibody is preadsorbed to remove any ... buffered aqueous glycerol solution A solution ... 2+ and Ca 2+ ), pH 7.3 ... (IgG, protease free) and 0.05% sodium azide A ...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
Biology Products: